argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 43.64B |
| Revenue (ttm) | 3.14B |
| Net Income (ttm) | 1.31B |
| Shares Out | 61.20M |
| EPS (ttm) | 19.83 |
| PE Ratio | 35.95 |
| Forward PE | 32.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,698 |
| Average Volume | 74,439 |
| Open | 717.40 |
| Previous Close | 713.00 |
| Day's Range | 714.00 - 718.40 |
| 52-Week Range | 456.60 - 810.00 |
| Beta | -0.11 |
| RSI | 39.05 |
| Earnings Date | Mar 5, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
News
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 9.76% on an annualized basis producing an average annual return of 23.04%. Currently, argenx has a market capitalization of ...
5 Top Stocks With High 2026 Earnings Growth Targets
The S&P 500 experienced sharp swings in 2025 due to shifts in trade policy, AI speculation, and rate cuts, while corporate profits remained resilient. Broader AI adoption and steady economic growth ar...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Argenx (ARGX) Downgraded by Baird Amid Valuation Concerns
Argenx (ARGX) Downgraded by Baird Amid Valuation Concerns
Argenx cut to Neutral at Baird after trial setback for Vyvgart
ARGX: Baird Downgrades argenx with Lower Price Target | ARGX Stock News
ARGX: Baird Downgrades argenx with Lower Price Target | ARGX Stock News
argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold
RBC Capital Raises Price Target for ARGX to $925, Maintains 'Outperform' | ARGX Stock News
RBC Capital Raises Price Target for ARGX to $925, Maintains 'Outperform' | ARGX Stock News
Wells Fargo Lowers Price Target for ARGX but Maintains Overweight Rating | ARGX Stock News
Wells Fargo Lowers Price Target for ARGX but Maintains Overweight Rating | ARGX Stock News
Touchstone Sands Capital International Growth Equity Fund Q3 2025 Portfolio Update
The Touchstone Sands Capital International Growth Fund (Class A Shares, Load Waived) underperformed the MSCI ACWI ex-U.S. Index for the quarter ended September 30, 2025. The top absolute contributors ...
Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease
Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx discontinues its Phase 3 UplighTED trial in ... Full story available on Benzinga.com
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx SE (NASDAQ: ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with mode...
Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse
Argenx stock toppled Monday after the biotech scrapped plans to develop its blockbuster drug, Vyvgart, for thyroid eye disease.
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Monday. Shares of argenx SE – ADR (NASDAQ: ARGX) fell sharply in pre-market trading after the company di...
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Monday.
Argenx (ARGX) Halts Phase 3 Trials for Thyroid Eye Disease Treatment
Argenx (ARGX) Halts Phase 3 Trials for Thyroid Eye Disease Treatment
Argenx To Discontinue UplighTED Studies In Thyroid Eye Disease Due To Futility
(RTTNews) - Argenx SE (ARGX ARGX.BR) announced on Monday that it is discontinuing its Phase 3 UplighTED studies evaluating Efgartigimod PH20 SC in adults with moderate to severe thyroid eye disease, b...
argenx to discontinue phase 3 UplighTED trials of efgartigimod in thyroid eye disease; stock drops
Stock Market Today: Dow Futures, S&P 500 Advance Ahead Of Key Economic Data: iRobot, Argenx, MindWalk In Focus
U.S. stock futures are up early Monday morning, following a mixed week that saw rotation out of expensive tech stocks in favor of value, despite the third consecutive interest rate cut on Wednesday. I...
Argenx, Navan And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects MindWalk Holdings Corp. (NASDAQ: HYFT) to repo...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
KROS vs. ARGX: Which Stock Is the Better Value Option?
KROS vs. ARGX: Which Stock Is the Better Value Option?
Wells Fargo Raises Price Target for ARGX, Maintains Overweight Rating | ARGX Stock News
Wells Fargo Raises Price Target for ARGX, Maintains Overweight Rating | ARGX Stock News
ARGX: Stifel Raises Price Target While Maintaining Buy Rating | ARGX Stock News
ARGX: Stifel Raises Price Target While Maintaining Buy Rating | ARGX Stock News